<DOC>
	<DOCNO>NCT01580215</DOCNO>
	<brief_summary>This observational prospective single arm multicentre study observe effect 5 year Zephyr endobronchial valve therapy emphysema .</brief_summary>
	<brief_title>Long Term Follow Investigation Endobronchial Valves Emphysema</brief_title>
	<detailed_description>Primary objective pulmonary function assess FEV1 secondary objective health relate quality life assess modify MRC dyspnea score COPD assessment test , survival five year . 2000 patient enrol study approximately 200 refer centre Germany . Patients follow 3 , 6 , 12 month , yearly 5 year . The study observe normal clinical practice . No investigation beyond perform normal clinical practice require exception two short questionnaire . Patients enrol study provide informed write consent anonymised data use study . Zephyr Endobronchial Valve CE mark fully reimburse Germany provide sponsor study obtain normal commercial channel accordance normal clinical practice .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Patients gender least 18 year age Understand voluntarily sign informed consent form . FEV1 &gt; 15 % predict &lt; 45 % predict RV &gt; 180 % predict Diagnosis emphysema CT evidence hyperinflation . Absence collateral ventilation accord Chartis Assessment System â€¢ Active pulmonary infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Valves</keyword>
	<keyword>Endobronchial</keyword>
	<keyword>Endoscopic lung volume reduction</keyword>
	<keyword>Pulmonx</keyword>
	<keyword>Zephyr</keyword>
	<keyword>Chartis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>COPD</keyword>
</DOC>